Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses. In ...

Moderna Inc (NASDAQ:MRNA) stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. On ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...